EYEPOINT PHARMACEUTICALS INC (EYPT)
US30233G2093 - Common Stock
EYEPOINT PHARMACEUTICALS INC
NASDAQ:EYPT (1/3/2025, 8:00:02 PM)
After market: 8.26 0 (0%)8.26
+0.23 (+2.86%)
Company Profile
EyePoint Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that treat eye disorders. The company is headquartered in Watertown, Massachusetts and currently employs 121 full-time employees. The company went IPO on 2005-01-27. The firm is focused on the business of developing and commercializing ophthalmic products for the treatment of eye diseases. The firm's pipeline leverages its Durasert technology (Durasert) for sustained intraocular drug delivery, including delivery of EYP-1901, is an investigational sustained delivery treatment for anti-vascular endothelial growth factor (anti-VEGF) mediated retinal diseases. Its additional pipeline programs include EYP-2301, a promising TIE-2 agonist, razuprotafib, formulated in Durasert E to potentially improve outcomes in serious retinal diseases. EYP-1901 is presently in Phase 2 clinical trials as a sustained delivery treatment for wet age-related macular degeneration (wet AMD), no proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The Company’s other products include YUTIQ, and DEXYCU.
Company Info
EYEPOINT PHARMACEUTICALS INC
480 Pleasant St Ste B300
Watertown MASSACHUSETTS 02472
P: 16179265000
CEO: Nancy Lurker
Employees: 121
Website: https://eyepointpharma.com/
EYPT News
20 days ago - EyePoint Pharmaceuticals, Inc.EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)WATERTOWN, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing...
a month ago - EyePoint Pharmaceuticals, Inc.EyePoint Announces First Patient Dosed in Second Global Phase 3 LUCIA Clinical Trial of DURAVYU™ for the Treatment of Wet Age-Related Macular Degeneration– Topline data for Phase 3 pivotal program anticipated in 2026 – WATERTOWN, Mass., Dec. 04, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc....
2 months ago - EyePoint Pharmaceuticals, Inc.EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)WATERTOWN, Mass., Nov. 18, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing...
2 months ago - EyePoint Pharmaceuticals, Inc.EyePoint Pharmaceuticals Announces Participation at Upcoming Investor ConferencesWATERTOWN, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing...
2 months ago - EyePoint Pharmaceuticals, Inc.EyePoint Pharmaceuticals Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional SharesWATERTOWN, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing...
2 months ago - Market News VideoInvestors Land EYPT Even Cheaper Than Its Secondary Stock OfferingEYPT Twits
Here you can normally see the latest stock twits on EYPT, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
